{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '10.2.', 'Schedule of Assessments', 'The schedule of assessments for this study is presented in Table 2, Table 3, and Table 4 (for', 'Parts 1, 2, and 3, respectively; study procedures are described in Section 11).', '53']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'Table 2.', 'Schedule of Assessments: Part 1 of Study BCX7353-302', 'Part 1', 'Assessment', 'Screening Period', 'Baseline', 'Double-Blind, Placebo-Controlled Study Drug Administration', 'Week 24', 'Screening', 'Run-in', 'Day 1a', 'Week 2\u00b0', 'Week 4', 'Week 8', 'Week 12', 'Week 18', 'Day 169d', 'Visita,', 'Perioda', 'Day 15', 'Day 29', 'Day 57', 'Day 85', 'Day 127', '(up to', '2 days', '2 days', '2 days', '2 days', '2 days', 'Week 10)', 'Informed consentb', 'X', 'In-clinic evaluations', 'X', 'X', 'X\u00b0', 'X', 'X', 'X', 'X', 'X', 'Telephone contacte', 'Inclusion-exclusion criteria', 'X', 'X', 'X', 'Medical history', 'X', 'X', 'HAE medical and medication', 'X', 'X', 'history\u00b9', 'Weight/height/BMI\u00ae', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Drugs of abuse screen', 'X', 'Physical examination', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Pregnancy test', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital signsk', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'FSH\u00b9', 'X', 'HIV, HCV, HBV serology', 'X', 'Diagnosis of HAE established\"', 'X', 'Attack qualification confirmation', 'X', 'Safety laboratory evaluationsh', 'X', 'X', 'Xc', 'X', 'X', 'X', 'X', 'X', 'Troponin I, Troponin T', 'X', 'X', 'X', 'X', 'X', 'X', 'C3 and C1-INH antigenic level', 'X', 'HLA typing\u00b0', 'X', 'Optional sample for possible', 'X', 'exploratory PG testingP', 'NGAL', 'X', 'X', 'X', 'X', 'X', 'X', 'CK-MB', 'X', 'X', 'X', 'X', 'X', 'X', 'Urinalysish', 'X', 'X', 'Xc', 'X', 'X', 'X', 'X', 'X', '12-lead ECG', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'EQ-5D-5L\"', 'X', 'X', 'X', 'X', 'X', 'X', 'AE-QoL, TSQM, WPAIs', 'X', 'X', 'X', 'X', 'X', 'X', '54']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'Part 1', 'Assessment', 'Screening Period', 'Baseline', 'Double-Blind, Placebo-Controlled Study Drug Administration', 'Week 24', 'Screening', 'Run-in', 'Day 1a', 'Week 2\u00b0', 'Week 4', 'Week 8', 'Week 12', 'Week 18', 'Day 169d', 'Visita,b', 'Perioda', 'Day 15', 'Day 29', 'Day 57', 'Day 85', 'Day 127', '(up to', '2 days', '2 days', '2 days', '2 days', '2 days', 'Week -10)', 'Concomitant medications', 'AEs', 'Randomization', 'X', 'X', 'e-diary instruction/review/', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'set-up\"', 'e-diary daily completion', 'Study drug dosing\"', 'Investigator confirmation of', 'attacks*', 'Study drug accountability/', 'X', 'X', 'X', 'X', 'X', 'X', 'dispensing', 'Plasma for PK analysisy', 'X', 'X', 'X', 'X', 'X', 'X', 'Plasma for kallikrein inhibitiony', 'X', 'X', 'X', 'X', 'X', 'X', 'Abbreviations: AE = adverse event; AE-QoL = Angioedema Quality of Life; ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate', 'aminotransferase; BMI = body mass index; C1-INH = C1 esterase inhibitor; C3 = complement 3; C4 = complement 4; CK-MB = creatine kinase MB isoenzyme;', 'CRF = case report form; ECG = electrocardiogram; e-diary = electronic diary; EQ-5D-5L = EuroQoI 5-dimensional, 5-level questionnaire; FSH = follicle', 'stimulating hormone; GGT = gamma glutamyl transferase; HAE = hereditary angioedema ; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human', 'immunodeficiency virus; HLA = human leukocyte antigen; IXRS = interactive (voice/web) response system; LLN = lower limit of normal; NGAL = neutrophil', \"gelatinase-associated lipocalin; PD = pharmacodynamic; PG = pharmacogenomic; PK = pharmacokinetic; QTcF = QT interval corrected using Fridericia's\", 'method; TSQM = Treatment Satisfaction Questionnaire for Medication; WPAI = Work Productivity and Activity Index.', 'a', 'The baseline visit must be held within 10 weeks (70 days) of the Screening visit, accommodating a run-in period of 14 days (minimum) to up to 56 days', '(maximum). The Investigator must gain Sponsor approval to enroll subjects who are not randomized within 10 weeks of the Screening visit; this may require', 'screening labs to be redrawn. Subjects will not be permitted to rescreen if they did not meet the HAE attack requirements during the run-in period.', 'b', 'Signing of informed consent may occur in advance of the Screening visit, which is defined as the visit where site-conducted screening procedures, including', 'e-diary dispensing, are performed.', 'c', 'The Week 2 visit will consist of monitoring liver function tests only (ALT, AST, GGT, total and direct bilirubin, ALP); urine and', 'additional', 'tubes', 'of', 'blood', 'may be required to accommodate possible reflex testing for abnormal GGT, AST or ALT (see Table 5). If preferred by the subject and clinical', 'site,', 'laboratory values may be drawn and resulted locally, with results entered into the CRF.', 'd', 'The last visit in Part 1 (Week 24) must occur the day following 24 weeks of study drug dosing in Part 1.', 'The Investigator (or designee) must call and talk to the subject at least weekly in between the Screening and Baseline visits and on-treatment during through', 'Week 24; alternative forms of interactive communication such as returned email and cellular text correspondence are acceptable. During all', 'calls,', 'the', '55']\n\n###\n\n", "completion": "END"}